EVAX announces business update and Q2 2025 results release date

Rhea-AI Filing Summary

Evaxion A/S, a clinical-stage TechBio company using AI-Immunology, furnished a press release announcing it will provide a business update and publish its second-quarter 2025 financial results on August 14, 2025. The Form 6-K states the press release is furnished as Exhibit 99.1 to the filing.

The filing itself contains no financial figures, operational metrics, or transaction details; it serves to notify investors of the timing and availability of the forthcoming update and results announcement.

Positive

• Clear scheduling of a business update and second-quarter 2025 financial results provides investors with a defined timeline for expected information
• Press release furnished as Exhibit 99.1, ensuring the announcement is publicly available through the Form 6-K

Negative

• No financial results or metrics are included in this filing
• Filing contains no operational updates or material transactions for investors to evaluate at this time

Insights

Financial Analyst

TL;DR: Routine results-timing announcement with no current financials provided; immediate material impact is limited.

The Form 6-K notifies the market that Evaxion will release a business update and its Q2 2025 financial results on August 14, 2025, and furnishes the related press release as Exhibit 99.1. Because the filing includes no revenue, expense, cash flow, or guidance figures, there is no new earnings data for valuation or modeling. Market-relevant information will depend on the content of the forthcoming release; this filing is primarily timing and disclosure logistics.

Corporate Governance Expert

TL;DR: The company met disclosure formalities by furnishing a press release via Form 6-K; the content is procedural rather than substantive.

By furnishing the press release as Exhibit 99.1, Evaxion follows standard disclosure practices for a foreign private issuer, ensuring public availability of the announcement. The filing is signed by the company's Interim CEO, indicating authorized disclosure. The absence of substantive financial or operational details in this filing means governance compliance is achieved, but investors must review the subsequent announcement for material information.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2025

Commission File Number: 001-39950

Evaxion A/S
(Exact Name of Registrant as Specified in Its Charter)

Dr. Neergaards Vej 5f
DK-2970 Hoersholm
Denmark
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F [ X ]      Form 40-F [   ]

INCORPORATION BY REFERENCE

This report on Form 6-K shall be deemed to be incorporated by reference in Evaxion A/S’s registration statements on Form S-8 (File No. 333-255064), on Form F-3 (File No. 333-265132), on Form F-1, as amended (File No. 333-266050), Form F-1 (File No. 333-276505), Form F-1 (File No. 333-279153), Form F-1 (File No. 333-283304), and Form F-3 (File No. 333- 285778), including any prospectuses forming a part of such registration statements and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

Press Release

On August 11, 2025, Evaxion A/S (the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, issued a press release titled "Evaxion to announce business update and second quarter 2025 financial results on August 14, 2025". A copy of the press release is furnished as Exhibit 99.1 to this report on Form 6-K.

Exhibits

Exhibit No.		Description
99.1		Evaxion to announce business update and second quarter 2025 financial results on August 14, 2025

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

			Evaxion A/S
			(Registrant)
Date: August 11, 2025		By:	/s/ Birgitte Rønø
			Birgitte Rønø
			Interim Chief Executive Officer

FAQ

What did Evaxion (EVAX) announce in this Form 6-K?

The company announced it will provide a business update and release its second-quarter 2025 financial results, and the related press release is furnished as Exhibit 99.1.

When will Evaxion release its Q2 2025 financial results?

The press release states the results are scheduled to be released on August 14, 2025.

Does this Form 6-K include the Q2 2025 financial figures?

No. The filing furnishes a press release announcing the timing but does not include any financial figures or operational metrics.

Where can investors find the press release referenced in the filing?

The press release is furnished as Exhibit 99.1 to this Form 6-K.

Who signed the Form 6-K for Evaxion?

The filing is signed on behalf of Evaxion by Birgitte Rønø, Interim Chief Executive Officer.